S100A10 and metabolic dysfunction-associated steatotic liver disease: As no rodent model faithfully recapitulate the whole complexity of human MASLD and HCC, we investigated the roles of S100A10 and S100A11 using complementary mouse models of MASLD, MASLD-driven HCC, or liver cancer without metabolic disorders.